International Guideline Harmonization Group
  • Home
  • About IGHG
    • Members
      • Core group
      • Guideline panels
        • Bone mineral density
        • Breast cancer
        • Cardiomyopathy
        • Central nervous system neoplasms
        • Colorectal cancer
        • Coronary artery disease
        • Dexrazoxane cardioprotection
        • Fatigue, mental health and psychosocial problems
        • Fertility preservation
        • Growth hormone treatment
        • Health promotion
        • Hepatic toxicity
        • Hypothalamic-pituitary dysfunction
        • Male gonadotoxicity
        • Metabolic syndrome
        • Nephrotoxicity
        • Neurocognitive problems
        • Obstetric care
        • Ototoxicty
        • Premature ovarian insufficiency
        • Pulmonary dysfunction
        • Splenic dysfunction
        • Thyroid cancer
        • Thyroid dysfunction
        • Anthracycline cardiotoxicity equivalence ratio
        • COVID-19 Statement
    • Collaborators
    • Funding sources
    • Methods
      • Process
      • Grading system
      • Topic selection
      • Publication
      • Handbook
  • Guidelines
    • Topics
      • Bone mineral density
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Breast cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Cardiomyopathy
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Central nervous system neoplasms
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Colorectal cancer
        • Guideline panel
      • Coronary artery disease
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Dexrazoxane cardioprotection
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fatigue
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fertility preservation
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publications
        • Guideline panel
      • Growth hormone treatment
        • Guideline panel
      • Health promotion
        • Guideline panel
      • Hepatic toxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Hypothalamic-pituitary dysfunction
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Male gonadotoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Mental health problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Metabolic syndrome
        • Guideline panel
      • Nephrotoxicity
        • Guideline panel
      • Neurocognitive problems
        • Guideline panel
      • Obstetric care
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Ototoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Premature ovarian insufficiency
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Psychosocial problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Pulmonary dysfunction
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Splenic dysfunction
        • Guideline panel
      • Thyroid cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Thyroid dysfunction
        • Guideline panel
      • Anthracycline cardiotoxicity equivalence ratio
        • Guideline panel
      • COVID-19 Statement
  • Patient education
  • News
  • Meetings
  • Contact

Male gonadotoxicity

Home Guidelines Topics Male gonadotoxicity Conclusions of evidence

  • Topics
    • Bone mineral density
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Breast cancer
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Cardiomyopathy
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Central nervous system neoplasms
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Colorectal cancer
      • Guideline panel
    • Coronary artery disease
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Dexrazoxane cardioprotection
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Fatigue
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Fertility preservation
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publications
      • Guideline panel
    • Growth hormone treatment
      • Guideline panel
    • Health promotion
      • Guideline panel
    • Hepatic toxicity
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Hypothalamic-pituitary dysfunction
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Male gonadotoxicity
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Mental health problems
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Metabolic syndrome
      • Guideline panel
    • Nephrotoxicity
      • Guideline panel
    • Neurocognitive problems
      • Guideline panel
    • Obstetric care
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Ototoxicity
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Premature ovarian insufficiency
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Psychosocial problems
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Pulmonary dysfunction
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Splenic dysfunction
      • Guideline panel
    • Thyroid cancer
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Thyroid dysfunction
      • Guideline panel
    • Anthracycline cardiotoxicity equivalence ratio
      • Guideline panel
    • COVID-19 Statement

Conclusions of evidence

The conclusions and levels of evidence of gonadotoxicity surveillance for male childhood, adolescent and young adult cancer survivors are presented in the following documents:

Conclusions and levels of evidence male gonadotoxicity surveillance

Conclusions of evidence tables from systematic search male gonadotoxicity surveillance

Summary of evidence from the supplemental literature search male gonadotoxicity surveillance

See The Lancet Oncology for the publication.

  • Contact
  • Disclaimer

© International Guideline Harmonization Group